Colorectal Cancer | Specialty

Dr. Taieb Discusses Primary Tumor Location in CRC

September 6th 2017

Julien Taieb, MD, head of the gastroenterology and gastrointestinal oncology department of the Georges Pompidou European Hospital, Paris Descartes University, discusses primary tumor location in colorectal cancer.

An Impactful Year for Molecular Testing in GI Cancers

August 23rd 2017

Antonia R. Sepulveda, MD, PhD, discusses the importance and utility of genetic testing in GI cancers, as well as noteworthy developments in microsatellite instability, BRAF, and KRAS testing in colorectal cancer.

FIT Assay Shows Overall Diagnostic Accuracy for CRC

August 19th 2017

Researchers have concluded from an analysis of multiple studies that the fecal immunochemical test has high overall diagnostic accuracy for screening asymptomatic patients at an increased risk for colorectal cancer (CRC) and moderate accuracy for diagnosing advanced neoplasia (AN).

Clinical Utility of Genetic Testing in CRC Continues to Grow

August 18th 2017

Manuel Hidalgo, MD, discusses his insight on the growth of genetic testing in CRC.

Dr. Modest Discusses the German AIO KRK0110 Study in CRC

August 18th 2017

Dominik P. Modest, MD, University of Munich, discusses the German AIO KRK0110 study in metastatic colorectal cancer.

Dr. O'Neil Discusses the Development of Biomarkers for CRC

August 11th 2017

Bert O’Neil, MD, the Joseph W. and Jackie J. Cusick Professor of Oncology, professor of medicine, and director of the Phase I and Gastrointestinal Oncology Programs at Indiana University, discusses the development of biomarkers for colorectal cancer (CRC).

Dr. Lenz on Need for New Treatment Strategies in Colorectal Cancer

August 11th 2017

Heinz-Josef Lenz, MD, FACP, associate director for Adult Oncology and co-leader of the Gastrointestinal Cancers Program, USC Norris Comprehensive Cancer Center, discusses the need for new treatment strategies in colorectal cancer.

Dr. Schmoll on the Objective of CHARTA for CRC

August 10th 2017

Hans-Joachim Schmoll, MD, head, Department of Oncology and Hematology, associate professor, Internal Medicine, Hematology/ Oncology, University Hospital Halle, discusses the objective of the CHARTA study for patients with colorectal cancer (CRC).

Dr. Diaz on Response Rates With Pembrolizumab for CRC

August 3rd 2017

Luis A. Diaz, MD, head of the division of Solid Tumor Oncology at Memorial Sloan Kettering Cancer Center, discusses the response rates of pembrolizumab (Keytruda) for patients with colorectal cancer (CRC).

Biomarker Basics: A Look at MSI's Growing Role

August 2nd 2017

The recent approval of 2 immunotherapies for the treatment of certain patients with tumors that exhibit microsatellite instability has propelled the emerging biomarker into clinical practice, prompting calls for broader genetic testing.

FDA Approves Nivolumab for MSI-H or dMMR Colorectal Cancer

August 1st 2017

The FDA has granted an accelerated approval to nivolumab for the treatment of adult and pediatric patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan.

HER2 Status in Colorectal Cancer

July 13th 2017

Evidence in BRAF-Mutant CRC Tumors

July 13th 2017

CRC: Emerging Immunotherapy Strategies in MSS Tumors

July 13th 2017

Pembrolizumab in MSI-H CRC Tumors

July 13th 2017

Role of Trifluridine/Tipiracil in CRC

July 13th 2017

Patient Selection for Regorafenib in CRC

July 13th 2017

Sequencing Considerations in MSS CRC Tumors

July 13th 2017

Exploring Second-Line Therapeutic Options in mCRC

July 13th 2017

Global Perspectives and Initial Decisions in mCRC

July 13th 2017